vs

Side-by-side financial comparison of ETHAN ALLEN INTERIORS INC (ETD) and Ultragenyx Pharmaceutical Inc. (RARE). Click either name above to swap in a different company.

Ultragenyx Pharmaceutical Inc. is the larger business by last-quarter revenue ($207.3M vs $149.9M, roughly 1.4× ETHAN ALLEN INTERIORS INC). ETHAN ALLEN INTERIORS INC runs the higher net margin — 7.8% vs -62.0%, a 69.9% gap on every dollar of revenue. On growth, Ultragenyx Pharmaceutical Inc. posted the faster year-over-year revenue change (25.9% vs -4.7%). ETHAN ALLEN INTERIORS INC produced more free cash flow last quarter ($-4.7M vs $-100.8M). Over the past eight quarters, Ultragenyx Pharmaceutical Inc.'s revenue compounded faster (38.0% CAGR vs 1.2%).

Ethan Allen Interiors Inc. is an American manufacturer and retailer of home furnishings, incorporated in Delaware with executive offices in Danbury, Connecticut. As of June 30, 2023, the company reported net annual sales of $791.4 million.

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

ETD vs RARE — Head-to-Head

Bigger by revenue
RARE
RARE
1.4× larger
RARE
$207.3M
$149.9M
ETD
Growing faster (revenue YoY)
RARE
RARE
+30.6% gap
RARE
25.9%
-4.7%
ETD
Higher net margin
ETD
ETD
69.9% more per $
ETD
7.8%
-62.0%
RARE
More free cash flow
ETD
ETD
$96.0M more FCF
ETD
$-4.7M
$-100.8M
RARE
Faster 2-yr revenue CAGR
RARE
RARE
Annualised
RARE
38.0%
1.2%
ETD

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
ETD
ETD
RARE
RARE
Revenue
$149.9M
$207.3M
Net Profit
$11.7M
$-128.6M
Gross Margin
60.9%
Operating Margin
9.5%
-54.7%
Net Margin
7.8%
-62.0%
Revenue YoY
-4.7%
25.9%
Net Profit YoY
-21.7%
3.5%
EPS (diluted)
$0.46
$-1.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ETD
ETD
RARE
RARE
Q4 25
$149.9M
$207.3M
Q3 25
$147.0M
$159.9M
Q2 25
$160.4M
$166.5M
Q1 25
$142.7M
$139.3M
Q4 24
$157.3M
$164.6M
Q3 24
$154.3M
$139.5M
Q2 24
$168.6M
$147.0M
Q1 24
$146.4M
$108.8M
Net Profit
ETD
ETD
RARE
RARE
Q4 25
$11.7M
$-128.6M
Q3 25
$10.5M
$-180.4M
Q2 25
$-115.0M
Q1 25
$9.6M
$-151.1M
Q4 24
$15.0M
$-133.2M
Q3 24
$14.7M
$-133.5M
Q2 24
$18.5M
$-131.6M
Q1 24
$13.0M
$-170.7M
Gross Margin
ETD
ETD
RARE
RARE
Q4 25
60.9%
Q3 25
61.4%
Q2 25
59.9%
Q1 25
61.2%
Q4 24
60.3%
Q3 24
60.8%
Q2 24
60.8%
Q1 24
61.3%
Operating Margin
ETD
ETD
RARE
RARE
Q4 25
9.5%
-54.7%
Q3 25
6.8%
-106.9%
Q2 25
9.5%
-64.8%
Q1 25
7.7%
-102.6%
Q4 24
11.5%
-74.3%
Q3 24
11.4%
-94.6%
Q2 24
13.4%
-79.1%
Q1 24
10.5%
-151.9%
Net Margin
ETD
ETD
RARE
RARE
Q4 25
7.8%
-62.0%
Q3 25
7.1%
-112.8%
Q2 25
-69.0%
Q1 25
6.7%
-108.5%
Q4 24
9.5%
-80.9%
Q3 24
9.5%
-95.7%
Q2 24
11.0%
-89.5%
Q1 24
8.8%
-156.8%
EPS (diluted)
ETD
ETD
RARE
RARE
Q4 25
$0.46
$-1.28
Q3 25
$0.41
$-1.81
Q2 25
$0.48
$-1.17
Q1 25
$0.37
$-1.57
Q4 24
$0.59
$-1.34
Q3 24
$0.57
$-1.40
Q2 24
$0.73
$-1.52
Q1 24
$0.50
$-2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ETD
ETD
RARE
RARE
Cash + ST InvestmentsLiquidity on hand
$139.3M
$421.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$478.2M
$-80.0M
Total Assets
$714.8M
$1.5B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ETD
ETD
RARE
RARE
Q4 25
$139.3M
$421.0M
Q3 25
$123.6M
$202.5M
Q2 25
$136.1M
$176.3M
Q1 25
$172.9M
$127.1M
Q4 24
$139.1M
$174.0M
Q3 24
$135.9M
$150.6M
Q2 24
$161.0M
$480.7M
Q1 24
$63.9M
$112.3M
Stockholders' Equity
ETD
ETD
RARE
RARE
Q4 25
$478.2M
$-80.0M
Q3 25
$475.5M
$9.2M
Q2 25
$482.4M
$151.3M
Q1 25
$479.2M
$144.2M
Q4 24
$478.8M
$255.0M
Q3 24
$474.7M
$346.8M
Q2 24
$483.0M
$432.4M
Q1 24
$477.4M
$140.3M
Total Assets
ETD
ETD
RARE
RARE
Q4 25
$714.8M
$1.5B
Q3 25
$737.1M
$1.2B
Q2 25
$737.1M
$1.3B
Q1 25
$738.7M
$1.3B
Q4 24
$732.6M
$1.5B
Q3 24
$737.7M
$1.5B
Q2 24
$744.9M
$1.6B
Q1 24
$742.2M
$1.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ETD
ETD
RARE
RARE
Operating Cash FlowLast quarter
$-1.8M
$-99.8M
Free Cash FlowOCF − Capex
$-4.7M
$-100.8M
FCF MarginFCF / Revenue
-3.2%
-48.6%
Capex IntensityCapex / Revenue
1.9%
0.5%
Cash ConversionOCF / Net Profit
-0.16×
TTM Free Cash FlowTrailing 4 quarters
$40.8M
$-472.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ETD
ETD
RARE
RARE
Q4 25
$-1.8M
$-99.8M
Q3 25
$16.8M
$-91.4M
Q2 25
$24.8M
$-108.3M
Q1 25
$10.2M
$-166.5M
Q4 24
$11.6M
$-79.3M
Q3 24
$15.1M
$-67.0M
Q2 24
$26.2M
$-77.0M
Q1 24
$23.7M
$-190.7M
Free Cash Flow
ETD
ETD
RARE
RARE
Q4 25
$-4.7M
$-100.8M
Q3 25
$14.4M
$-92.7M
Q2 25
$22.9M
$-110.7M
Q1 25
$8.2M
$-167.8M
Q4 24
$7.8M
$-79.5M
Q3 24
$11.5M
$-68.6M
Q2 24
$24.2M
$-79.0M
Q1 24
$21.4M
$-193.9M
FCF Margin
ETD
ETD
RARE
RARE
Q4 25
-3.2%
-48.6%
Q3 25
9.8%
-58.0%
Q2 25
14.3%
-66.5%
Q1 25
5.7%
-120.5%
Q4 24
5.0%
-48.3%
Q3 24
7.4%
-49.2%
Q2 24
14.3%
-53.7%
Q1 24
14.6%
-178.2%
Capex Intensity
ETD
ETD
RARE
RARE
Q4 25
1.9%
0.5%
Q3 25
1.6%
0.8%
Q2 25
1.2%
1.5%
Q1 25
1.4%
1.0%
Q4 24
2.4%
0.1%
Q3 24
2.3%
1.2%
Q2 24
1.2%
1.4%
Q1 24
1.6%
3.0%
Cash Conversion
ETD
ETD
RARE
RARE
Q4 25
-0.16×
Q3 25
1.61×
Q2 25
Q1 25
1.06×
Q4 24
0.77×
Q3 24
1.02×
Q2 24
1.42×
Q1 24
1.83×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ETD
ETD

Wholesale Segment$79.1M53%
Upholstery Furniture$44.9M30%
Case Goods$20.4M14%
Manufactured Product Other$6.4M4%

RARE
RARE

Royalty$105.6M51%
Products$101.7M49%

Related Comparisons